Stay updated on Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe page's revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2. This appears to be a minor version update with no visible changes to study content.SummaryDifference0.0%

- Check58 days agoChange DetectedFallopian tube cancer was added to the conditions list and Genetic and Rare Diseases Information Center resources were added. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check65 days agoChange DetectedRevision tag updated from v3.4.0 to v3.4.1. No visible changes to the study details were observed.SummaryDifference0.0%

- Check72 days agoChange DetectedAdded a 'Show glossary' option and the 'No FEAR Act Data' text. Updated footer labels to 'Last Update Submitted that Met QC Criteria' and introduced 'Revision: v3.4.0'.SummaryDifference0.2%

- Check87 days agoChange DetectedThe page revision label was updated from v3.3.3 to v3.3.4; there are no substantive changes to study details, eligibility criteria, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.